QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Price, News & Analysis

$28.39
-0.11 (-0.39%)
(As of 05:21 PM ET)
Today's Range
$27.27
$29.00
50-Day Range
$15.62
$29.18
52-Week Range
$6.40
$30.27
Volume
1.32 million shs
Average Volume
2.30 million shs
Market Capitalization
$2.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.43

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
31.8% Upside
$37.43 Price Target
Short Interest
Bearish
13.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Dyne Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$49.84 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.23) to ($3.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.02 out of 5 stars

Medical Sector

212th out of 938 stocks

Pharmaceutical Preparations Industry

87th out of 426 stocks

DYN stock logo

About Dyne Therapeutics Stock (NASDAQ:DYN)

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

DYN Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Dyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brumm
Dyne Therapeutics Announces CEO Transition
Dyne Therapeutics (NASDAQ: DYN)
DYN Apr 2024 30.000 put
DYN Apr 2024 22.500 call
DYN Apr 2024 30.000 call
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DYN
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.43
High Stock Price Target
$56.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+30.7%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-235,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.49 per share

Miscellaneous

Free Float
55,002,000
Market Cap
$2.35 billion
Optionable
Optionable
Beta
0.95
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price target for 2024?

7 analysts have issued 12-month target prices for Dyne Therapeutics' stock. Their DYN share price targets range from $22.00 to $56.00. On average, they anticipate the company's share price to reach $37.43 in the next twelve months. This suggests a possible upside of 31.8% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2024?

Dyne Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, DYN shares have increased by 113.5% and is now trading at $28.39.
View the best growth stocks for 2024 here
.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DYN earnings forecast
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.17.

What ETF holds Dyne Therapeutics' stock?

Morningstar US Small Growth holds 9,078 shares of DYN stock, representing 2.59% of its portfolio.

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fcpm Iii Services B.V. (9.99%), Vanguard Group Inc. (3.80%), Vanguard Group Inc. (3.80%), Vida Ventures Advisors LLC (3.38%), Franklin Resources Inc. (3.12%) and Wasatch Advisors LP (2.74%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell.
View institutional ownership trends
.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners